Beam Therapeutics (BEAM)
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Beam Therapeutics (BEAM)
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Key Insights
Critical company metrics and information
Share Price
$27.26Market Cap
$2.26 BillionTotal Outstanding Shares
82.81 Million SharesTotal Employees
374Dividend
$0.23 Per Share QuarterlyIPO Date
February 6, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockPhone Number
857-327-8775Address
26 landsdowne street, Cambridge, MA, 02139Homepage
https://www.beamtx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $59.02 Million |
| Net Cash Flow | $59.02 Million |
| Net Cash Flow From Financing Activities, Continuing | $38.01 Million |
| Net Cash Flow From Investing Activities | $156.83 Million |
| Net Cash Flow From Operating Activities, Continuing | $-135.81 Million |
| Net Cash Flow From Operating Activities | $-135.81 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $165.66 Million |
| Net Income/Loss Attributable To Parent | $-143.59 Million |
| Costs And Expenses | $491.83 Million |
| Nonoperating Income/Loss | $40.49 Million |
| Diluted Earnings Per Share | $-1.57 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Wages | $13.71 Million |
| Current Liabilities | $166.24 Million |
| Equity Attributable To Parent | $791.32 Million |
| Equity | $791.32 Million |
| Other Non-current Assets | $112.33 Million |
| Liabilities | $380.05 Million |
Historical Dividends
Current dividend: $0.23 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jan 22, 2014 | Mar 3, 2014 | Feb 6, 2014 | $0.225 | Quarterly |
| Sep 19, 2013 | Dec 2, 2013 | Nov 6, 2013 | $0.225 | Quarterly |
| Jul 31, 2013 | Sep 3, 2013 | Aug 14, 2013 | $0.23 | Quarterly |
| Apr 24, 2013 | Jun 3, 2013 | May 8, 2013 | $0.225 | Quarterly |
| Jan 25, 2013 | Mar 1, 2013 | Feb 6, 2013 | $0.225 | Quarterly |
| Oct 4, 2012 | Dec 3, 2012 | Nov 7, 2012 | $0.205 | Quarterly |
Related Companies
View additional S&P 500 companies similar to Beam Therapeutics (BEAM)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.